SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Rhea-AI Summary

SpringWorks Therapeutics (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focusing on severe rare diseases and cancer, has announced its upcoming second quarter 2024 financial results report. The company will host a live conference call and webcast on Wednesday, August 7, 2024, at 8:30 a.m. ET to present the results and discuss recent business updates. Interested parties can join the webcast to view the presentation slides or pre-register for the conference call to participate by phone. A replay of the webcast will be available for a time on the company's investor relations website.

STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates.

To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company’s website at https://ir.springworkstx.com.

About SpringWorks Therapeutics

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO^® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com

FAQ

When will SpringWorks Therapeutics (SWTX) report its Q2 2024 financial results?

SpringWorks Therapeutics (SWTX) will report its second quarter 2024 financial results on Wednesday, August 7, 2024.

What time is SpringWorks Therapeutics' (SWTX) Q2 2024 earnings call scheduled for?

SpringWorks Therapeutics' (SWTX) Q2 2024 earnings call is scheduled for 8:30 a.m. ET on Wednesday, August 7, 2024.

How can investors access SpringWorks Therapeutics' (SWTX) Q2 2024 earnings webcast?

Investors can access SpringWorks Therapeutics' (SWTX) Q2 2024 earnings webcast by clicking the link provided in the press release or visiting the Investors & Media section of the company's website.

Will SpringWorks Therapeutics (SWTX) provide a replay of its Q2 2024 earnings call?

Yes, SpringWorks Therapeutics (SWTX) will provide a replay of the Q2 2024 earnings webcast for a time on the Investors & Media section of the company's website.